A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir

HIV Medicine

Volumn 5, Issue 1, 2004, Pages 15-17

  Mauss, Stefan ^a   Scholten, S ^b   Wolf, E ^c   Berger, F ^a   Schmutz, G ^a   Jaeger, H ^c   Kurowski, M ^d   Rockstroh, J K ^b  

^a Center for HIV and Hepatogastroenterology   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c MUC Research GmbH and MVZ Karlsplatz   (Germany)

^d NONE

Author keywords

Amprenavir; Drug interactions; Lopinavir; Pharmacokinetics; Ritonavir

Indexed keywords

AMPRENAVIR; LOPINAVIR; RITONAVIR;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROLOGY;

ANTI-HIV AGENTS; CARBAMATES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HUMANS; PROSPECTIVE STUDIES; PYRIMIDINONES; RITONAVIR; SULFONAMIDES;

EID: 1242296303     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00179.x     Document Type: Article

References (8)

1. Van Heeswijk RPG, Veldkamp A, Mulder JW et al. Combination of protease inhibitors for the treatment of HIV-1 infected patients: a review of pharmacokinetics and clinical experience. Antiviral Ther 2002; 6: 201-229.
2. Fätkenheuer G, Romer K, Kamps R, Salzberger B, Burger D. Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients. AIDS 2001; 15: 2334-2335.
3. Khanlou H, Graham E, Brill M, Farthing C. Drug interaction between amkprenavir and lopinavir/ritonavir in salvage therapy. AIDS 2002; 16: 797-798.
4. Mauss S, Schmutz G, Kuschak D. Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir. AIDS 2002; 16: 296-297.
5. Kurowski M, Müller M, Arasteh K, Moecklinghoff C. Simultaneous monitoring of five protease-inhibitors in HIV-infected patients by LC-tandem mass spectrometry. 39th Interscience conference on antimicrobial agents and chemotherapy. San Francisco, CA, 26-29 September 1999.
6. Murphy RL, Bran S, Hicks C et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HFV-1 infection: 48-week results. AIDS 2001; 15: F1-179.
7. Back D, Gatti G, Fletcher C et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16 (Suppl. 1): S5-S37.
8. Markowitz M, Saag M, Powderly WG et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333: 1534-1539.